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Mast cells accumulate in tissues undergoing angiogenesis during tumor growth, wound 
healing, and tissue repair. Mast cells can secrete angiogenic factors such as vascular 
endothelial growth factor (VEGF). Ionizing irradiation has also been shown to have 
angiogenic potential in malignant and nonmalignant diseases. We observed that low-dose 
irradiation fosters mast cell–dependent vascular regeneration in a limb ischemia model. 
Irradiation promoted VEGF production by mast cells in a matrix metalloproteinase-9 (MMP-9)–
dependent manner. Irradiation, through MMP-9 up-regulated by VEGF in stromal and 
endothelial cells, induced the release of Kit-ligand (KitL). Irradiation-induced VEGF promoted 
migration of mast cells from the bone marrow to the ischemic site. Irradiation-mediated 
release of KitL and VEGF was impaired in MMP-9–deficient mice, resulting in a reduced 
number of tissue mast cells and delayed vessel formation in the ischemic limb. Irradiation-
induced vasculogenesis was abrogated in mice deficient in mast cells (steel mutant, Sl/Sl
 
d
 
 
mice) and in mice in which the VEGF pathway was blocked. Irradiation did not induce 
progenitor mobilization in Sl/Sl
 
d
 
 mice. We conclude that increased recruitment and 
activation of mast cells following irradiation alters the ischemic microenvironment and 
promotes vascular regeneration in an ischemia model. These data show a novel mechanism 
of neovascularization and suggest that low-dose irradiation may be used for therapeutic 
angiogenesis to augment vasculogenesis in ischemic tissues.
 
Blood vessels form as a result of vasculogenesis
from circulating endothelial progenitors (CEPs),
angiogenesis, and arteriogenesis through endo-
thelial sprouting from pre-existing vessels. Pla-
cental growth factor (PlGF) and vascular endo-
thelial growth factor (VEGF) not only support
transient (1) and permanent revascularization of
ischemic tissue (2) but also promote mobilization
of hematopoietic and/or endothelial progenitor
cells (3, 4). They signal through a family of
closely related receptor tyrosine kinases consisting
of VEGF receptor 1 (VEGFR-1 or Flt-1),
VEGFR-2 (Flk-1), and VEGFR-3 (Flt-3). Mast
cells also play a role in the formation of new
blood vessels. They originate from pluripotent
progenitor cells in BM and circulate in small
numbers as committed progenitors. Mast cell
precursors produce the matrix metalloproteinase
(MMP)-9/gelatinase B, which may be essential
for mast cell migration into tissues (5). The pres-
ence of mast cells in tissues depends on the action
of their transmembrane tyrosine kinase receptor,
c-kit, and its ligand, kit-ligand (KitL, mast cell
growth factor), which is expressed on fibroblasts
and stromal cells, from where it can be released.
Ionizing irradiation (IR) has been shown to
have angiogenic potential in malignant and
nonmalignant diseases (6–8). Although VEGF is
an important regulator of vasculogenesis/angio-
genesis triggered by IR, hypoxia, and growth
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factors, the source and processes supplying VEGF are not well
studied. Moreover, the molecular basis of IR-induced angio-
genesis is poorly understood. Endothelial cell (EC) viability is
not affected at doses of up to 10 Gy, and VEGF has a radio-
protective effect on ECs, correlating with the up-regulation of
VEGFR-2 in irradiated ECs (9). Up-regulation of IR-
induced PlGF in tumor cells causes increased microvessel
density in xenografts (10). Prevention of IR-induced angio-
genic responses therefore provides an important strategy to
prevent tumor recurrence (11). On the other hand, low-dose
IR accelerates wound healing and improves neovasculariza-
tion by promoting EC proliferation (12).
We have investigated the mechanism regulating IR-
induced vasculogenesis/angiogenesis in a MMP-9–deficient
(MMP-9
 
 
 
/
 
 
 
) mouse model. MMPs are involved in many as-
pects of organ regeneration and angiogenesis by promoting
the release of extracellular matrix–bound or cytokines or
angiogenesis-modulating extracellular matrix fragments,
thereby regulating angiogenesis (13). We demonstrate that
MMP-9 plays an important role in stem cell mobilization
from the BM niche (4, 14). We now provide evidence that
IR-induced vasculogenesis depends in part on MMP-9–
mediated release of VEGF from mast cells. Using mast cell–
deficient mice or blockade of the VEGF signaling pathway,
we demonstrate that KitL and VEGF, when released after
IR, not only promote progenitor mobilization but more im-
portantly are potent chemoattractants for mast cells, which
serve as a major source of VEGF at the ischemic site.
 
RESULTS
Impaired BM recovery and progenitor mobilization 
after irradiation in MMP-9–deficient mice
 
CEPs contribute to vessel formation at the ischemic site (15).
We initially asked whether IR releases hematopoietic progen-
Figure 1. Irradiation-induced BM regeneration and progenitor 
mobilization are MMP-9–dependent and coincide with an increase 
in angiogenic factors. MMP-9 /  and MMP-9 /  mice were irradiated 
with 6.5 Gy. (A) BM cell number (n   8/group), (B) CFU-Cs (n   3/group), 
and (C) CFU-ECs (n   6/group) were assessed in BM cells following IR 
(two separate experiments). (D) White blood cell counts (n   30/group). 
(E, top) BM cell lysates were assayed via Western blot analysis. (bottom) 
BM cells obtained after IR were cultured overnight in serum-free medium. 
BM supernatants were assayed for active MMP-9 via zymography (n   2; 
representative experiment shown). Zymographic blot and densitometric 
quantification are shown. (F) Immunohistochemistry of BM sections before 
(a) and after IR (b–d) for MMP-9 (brown staining, arrows) in MMP-9 /  
and MMP-9 /  mice (original magnification,  100; insert,  200). Number 
of (G) CFU-Cs and (H) CFU-ECs was determined in peripheral blood of 
irradiated mice. (I, J) Plasma of MMP-9 /  and MMP-9 /  mice was assayed 
for (I) KitL (n   5/group) and (J) VEGF (n  5 /group) levels via ELISA. 
*P   0.05 comparing the MMP-9 /  and MMP-9 /  group. Error bars 
indicate mean   SEM. 
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itors and/or CEP into circulation in an MMP-dependent
manner. Both MMP-9–deficient and WT mice tolerated sub-
lethal IR at doses of 1.0, 2.0, 6.5, and 7.5 Gy (unpublished
data), and showed no difference in the survival of a lethal IR
dose (9.5 Gy). BM hematopoietic recovery after a sublethal
dose of 6.5 Gy, as determined by BM cellularity (Fig. 1 A),
the hematopoietic colony-forming unit cells (CFU-Cs) (Fig. 1
B), CFU endothelial cell (CFU-EC) recovery (Fig. 1 C), and
peripheral blood cell count recovery (Fig. 1 D) was delayed in
MMP-9
 
 
 
/
 
 
 
 mice compared with controls. These data are in
accordance with our previous study in which we showed that
MMP-9–mediated KitL release is essential for BM cell recov-
ery, because the delayed BM recovery of MMP-9
 
 
 
/
 
 
 
 mice af-
ter 5-fluorouracil could be restored by soluble KitL (14).
When WT mice were irradiated with a sublethal dose of
6.5 Gy as total body IR (TBI), MMP-9 expression in superna-
tants of BM cells increased starting from day 7 until day 21 after
IR (Fig. 1 E), while TIMP-1 expression did not change (not
depicted). Supernatants of BM cells of unirradiated animals had
only small amounts of pro– and active forms of MMP-9. Plasma
levels of pro–MMP-9 also increased after IR (Fig. S1 A, avail-
able at http://www.jem.org/cgi/content/full/jem.20050959/
DC1). Immunoreactive MMP-9 was low in unirradiated mice
(Fig. 1 F a) but was highly expressed 6 and 12 d after TBI in
close contact with osteoblasts (Fig. 1 F, c and d). By day 30 after
IR, MMP-9 staining was found in the central areas of the BM
(Fig. 1 F, d). By contrast, MMP-2 expression showed no major
change as determined by zymography (Fig. S1 B).
Figure 2. Low-dose irradiation and HL ischemia induce progenitor 
mobilization. (A–C) MMP-9 /  and MMP-9 /  mice were irradiated with 
2 Gy. (A) BM cell number per femur following low-dose IR and (B) white 
blood cell recovery (n   8) was determined (*P   0.05 comparing MMP-9 /  
with MMP-9 /  mice). (C) BM cells were collected after IR and cultured 
overnight in serum-free conditions. (a) Supernatants were assayed via 
zymography for active MMP-9 and densitometric quantification (small 
blot; n   3). (b) Immunohistochemical staining for MMP-9 in BM sections 
of irradiated animals. Arrows indicate staining for MMP-9. (D, E) Plasma 
was assayed for KitL (D) and VEGF (E) via ELISA (n   2; *P   0.05 comparing 
MMP-9 /  group vs. MMP-9 /    2 Gy, MMP-9 / , or MMP-9 /    2 Gy). 
(F–J) HL ischemia was induced in MMP-9 /  and MMP-9 /  mice followed 
by low-dose 2 Gy IR or no IR. (F) Muscle tissue of mice irradiated with 
2 Gy was stained for MMP-9 in WT animals on day 0 and day 10. Vessels 
stained strongly positive for MMP-9 after IR. Arrows indicate positively 
staining vessels. (G, H) PBMCs were analyzed for the presence of CFU-Cs 
(G) and CFU-ECs (H) (n   6/group). (I) Plasma VEGF was measured (n   2; 
3–5 mice/group). (J) PBMCs isolated 7 d after IR and HL ischemia was 
induced were stained for VEGFR-2/Cy2 and c-kit/PE and analyzed via 
FACS (left). Single- and double-positive VEGFR-2/c-kit PBMCs isolated 
with a MoFlo cell sorter were stained for Toluidine blue (right). Error bars 
indicate mean   SEM. 
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What is the role of increased MMP-9 activity in the BM
endothelium after IR? Under steady-state conditions, the
number of capillaries, as a direct measure of BM endothe-
lium, was not different between MMP-9
 
 
 
/
 
 
 
 and MMP-9
 
 
 
/
 
 
 
mice. BM vascular recovery following IR was impaired in
irradiated MMP-9
 
 
 
/
 
 
 
 mice, as estimated by determining the
number of capillaries (Fig. S1, C and D). The VEGFR1
 
 
 
(Fig. S1 E) and VEGFR2
 
 
 
 cell fractions (Fig. S1 F) were
lower in MMP-9
 
 
 
/
 
 
 
 mice, and their recovery was delayed.
 
IR stimulates hematopoietic and endothelial 
progenitor mobilization
 
We observed enhanced mobilization of CFU-Cs (Fig. 1 G)
and CFU-ECs (Fig. 1 H) into circulation in irradiated WT,
but not in MMP-9
 
 
 
/
 
 
 
 mice. Which factors govern progeni-
tor mobilization? We recently reported that plasma levels of
stromal cell–derived factor 1 (SDF-1 or CXCL12) and KitL
are elevated following 5-fluorouracil treatment (stress-hema-
topoiesis) (4, 14). Here, we show that IR increases stem
cell–active mobilization factors, including plasma KitL (Fig.
1 I), VEGF (Fig. 1 J), SDF-1 (Fig. S1 G), and PlGF (Fig. S1
H) in a partly MMP-9–dependent manner.
IR at high doses might have adverse effects. If IR could
ultimately be used to improve ischemia-related diseases,
low-dose IR could have efficacy in progenitor recovery and
growth factor production. Hematopoietic recovery follow-
ing low-dose IR was delayed in MMP-9
 
 
 
/
 
 
 
 as compared
with MMP-9
 
 
 
/
 
 
 
 mice, as assayed by the number of BM cells
per femur (Fig. 2 A). We observed that post-IR–induced
leukopenia was attenuated after an IR dose of 2 Gy (Fig. 2
B) in MMP-9
 
 
 
/
 
 
 
 
 
mice. Significantly, low-dose IR induced
MMP-9 expression in BM cells (Fig. 2 C) and augmented
plasma KitL (Fig. 2 D), PlGF (Fig. S2 A, available at http://
www.jem.org/cgi/content/full/jem.20050959/DC1), and
VEGF levels (Fig. 2 E) in an MMP-9–dependent manner.
Moreover, circulating CFU-C and CFU-EC release (Fig. S2
B and C, available at http://www.jem.org/cgi/content/full/
jem.20050959/DC1) was increased after low-dose IR in
MMP-9
 
 
 
/
 
 
 
 but not MMP-9
 
 
 
/
 
 
 
 mice.
To test the potential therapeutic pro-angiogenic effect
of low-dose IR and its regulation by MMP-9, we chose a
mouse model of hind limb (HL) ischemia. Operated
MMP-9
 
 
 
/
 
 
 
 mice receiving an IR dose of 2 Gy did not
show pad necrosis (unpublished data), whereas unirradiated
controls showed necrotic changes. In muscle tissue of
MMP-9
 
 
 
/
 
 
 
 mice, larger vessels stained positive for MMP-9
(Fig. 2 F) after IR (2 Gy). Kidney, lung, and spleen tissue
showed no difference in MMP-9 staining before or after
IR (unpublished data). HL ischemia increased mobilization
of CFU-Cs (Fig. 2 G) and CFU-ECs (Fig. 2 H). However,
HL ischemia, in combination with IR, resulted in a pro-
found increase in CFU-Cs (up to 30-fold compared with
steady-state values) and CFU-ECs, which coincided
with peaks in plasma levels of VEGF (Fig. 2 I), KitL (Fig.
S2 D, available at http://www.jem.org/cgi/content/full/
jem.20050959/DC1), and PlGF (Fig. S2 E) in MMP-9
 
 
 
/
 
 
 
,
but not in MMP-9
 
 
 
/
 
 
 
 
 
mice. Plasma VEGF, KitL, and PlGF
levels rose further (two to threefold) after IR in these mice
(Fig. 2 I; and Fig. S2, D and E). Soluble factors known to
be involved in ischemic regeneration (16, 17)—such as
monocyte chemotactic protein 1 (MCP-1; Fig. S2 F),
transforming growth factor 
 
 
 
 (TGF-
 
 
 
; Fig. S2 G), and ba-
sic fibroblast growth factor (unpublished data)—showed
slight increases following HL ischemia induction, but were
identical in MMP-9
 
 
 
/
 
 
 
 and MMP-9
 
 
 
/
 
 
 
 mice. Importantly,
IR did not further increase the plasma levels of these factors
in either group of mice.
To understand which cell types increase after IR, we ana-
lyzed peripheral blood mononuclear cells (PBMCs) via FACS
(Becton Dickinson) using mAbs against c-kit and VEGFR-2
after IR. No differences were found in the number of
VEGFR
 
 
 
/c-kit
 
 
 
 cells following HL ischemia or after IR. HL
ischemia mobilized VEGFR-2
 
 
 
/c-kit
 
 
 
 cells, most likely
comprised of ECs (18) in MMP-9 /  mice, but to a lower
extent in MMP-9 /  mice (Fig. 2 J). IR further augmented
the release of VEGFR-2 /c-kit  cells into circulation in a
MMP-9–dependent manner. Importantly, IR increased the
VEGFR-2 /c-kit  cell population in MMP-9 /  but not
MMP-9 /  mice. Toluidine blue O  cells were the major
constituent of the VEGFR-2 /c-kit  fraction (Fig. 2 J).
Low-dose IR stimulates blood vessel formation 
in ischemic limbs
Revascularization of the ischemic limb was macroscopically
delayed in MMP-9 /  mice (unpublished data), with fewer
von Willebrand factor (vWF)-positive capillaries, resulting in
significantly more necrosis compared with MMP-9 /  mice
(Fig. 3, A–C). In addition, the number of vessels covered
with smooth muscle cells (SMCs) was higher in HL ische-
mia–induced MMP-9 /  mice compared with MMP-9 / 
animals (Fig. 3 A).
After IR, HL ischemia–induced MMP-9 /  mice
showed few signs of necrosis compared with unirradiated
controls (Fig. 3, A and B). Muscle tissue from HL ische-
mia–induced MMP-9 /  mice showed vast areas of ne-
crotic tissue. IR only slightly decreased the necrotic area
in these animals. IR under ischemic conditions increased
the number of capillaries in MMP-9 /  mice but only
slightly in MMP-9 /  mice (Fig. 3 C). Restoration of
vascular function as measured by thermography (Fig. 3, A
and D) and laser Doppler (Fig. 3, A and E) paralleled the
vascular regeneration. Ten days after induction of HL is-
chemia, laser Doppler analysis revealed decreased blood
flow in HL ischemia–induced MMP-9 /  compared with
MMP-9 /  mice (Fig. 3 E). IR of HL ischemia–induced
MMP-9 /  mice increased both mean temperature (Fig.
3, A and D) and blood flow (Fig. 3, A and E) compared
with nonirradiated controls. In contrast, IR of HL ische-
mia–induced MMP-9 /  mice only slightly improved
mean temperature (Fig. 3, A and D) and blood flow (Fig.
3, A and E). Upon histological examination, necrotic
area, density of vWF  vessels, and perfusion of irradiatedJEM VOL. 202, September 19, 2005 743
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animals without induction of ischemia was not different
in irradiated compared with unirradiated muscle tissue in
MMP-9 /  or MMP-9 /  mice (Fig. 3, B–E). These data
suggest that low-dose IR alone does not cause visible
changes in the muscle microenvironment, but applied un-
der ischemic conditions stimulates angiogenesis.
IR increases the number of tissue-resident mast cells
The increase in Toluidine blue–positive mast cell–like
cells in circulation following IR (Fig. 2 J) led us to hy-
pothesize that IR improves mast cell migration into ische-
mic tissue. A higher number of mast cells was found in is-
chemic muscle tissue from MMP-9 /  compared with
MMP-9 /  mice (Fig. 4 A, a–d). Mast cells were identi-
fied as Toluidine blue– and (unpublished data) mast cell
tryptase–positive cells. Using adjacent tissue sections,
we detected VEGF mRNA in mast cells via in situ hy-
bridization (Fig. 4 A, e–h), implying that these cells are
the major source of VEGF in the tissues after ischemia
and IR. Staining of adjacent sections with VEGFR-2
mAb revealed that both mast cells and ECs stained posi-
tive for VEGFR-2 (Fig. 4 A, i–l). IR further augmented
the number of mast cells in the muscle tissue of MMP-9 / 
mice but not MMP-9 /  mice (Fig. 4 A, a–d, m).
Because mice had been exposed to TBI, we determined
the number of mast cells in other tissues. The number of
Toluidine blue–positive mast cells was higher 14 d after
low-dose IR in the skin (Fig. 4 B, a and b) of MMP-9 / 
mice, but not MMP-9 /  mice, compared with untreated
controls. As a measure of mast cell activation, we deter-
mined histamine levels in irradiated and unirradiated WT
mice. IR increased plasma histamine levels threefold as
compared with unirradiated controls (Fig. S2 H).
Mast cell–mediated VEGF release after low-dose irradiation 
mediates angiogenesis and is impaired in 
MMP-9–deficient mice
KitL and VEGF promote mast cell migration (19, 20), and mast
cells show baseline MMP-9 activity. We therefore examined
whether the decreased number of mast cells in MMP-9 / 
Figure 3. Low-dose IR-mediated revascularization is delayed in 
MMP-9 /  mice. (A–E) HL ischemia was induced in MMP-9 /  and 
MMP-9 /  mice. Mice then received a single low-dose TBI (2 Gy) or no IR. 
(A) Muscle sections from the ischemic limb were stained with hematoxylin-
eosin for vWF via immunohistochemistry and with the endothelial marker 
CD31 (red fluorescence) and SMA (green fluorescence). Mice were analyzed 
for mean body temperature via thermography 10 d (n   6/group) and 
laser Doppler for blood perfusion in the ligated limb 14 d after vessel 
ligation. (B) Necrosis area of hematoxylin-eosin–stained muscle sections 
was quantified (n   3/group). (C) vWF  vessels were counted in muscle 
sections 7 d following ligation and concomitant IR (n   3/group). (D) Quanti-
fication of the mean temperature 10 d after ligation of the artery and vein 
(n   6/group). (E) Blood flux was still low in MMP-9 /  mice on day 14, 
whereas blood flux had returned to levels seen in nonligated limbs in 
irradiated MMP-9 /  mice. *P   0.001 comparing MMP-9 /  mice with 
HL ischemia without and with IR. **P   0.05 comparing MMP-9 /  mice 
with HL ischemia without and with IR or comparing MMP-9 /  and 
MMP-9 /  with HL ischemia. Error bars indicate mean   SEM.LOW-DOSE IRRADIATION PROMOTES TISSUE REVASCULARIZATION | Heissig et al. 744
mouse tissue was due to a migratory defect of mast cells toward
KitL and/or VEGF. In a transwell migration assay, KitL and
VEGF induced migration of MMP-9 /  mast cells (Fig. 4 C)
but not MMP-9 /  mast cells. VEGF-mediated migration of
MMP-9 /  mast cells was partially blocked by neutralizing an-
tibodies against VEGFR-1 or VEGFR-2 but was completely
blocked by addition of an MMP inhibitor (MPI CGS 27023A).
PT18 cells (mast cell line) and MMP-9 /  mast cells
showed baseline VEGF secretion (Fig. 4 D), which was sig-
nificantly augmented by 2 Gy IR. Addition of KitL only
marginally elevated VEGF levels in supernatant of mast cell
cultures. VEGF release depended on the presence of MMP-9,
because baseline VEGF secretion from MMP-9 /  mast cells
was low, and IR only slightly enhanced VEGF release (Fig.
S2 I). The observed differential release of VEGF from mast
cells with and without IR was not due to changes in mast
cell numbers (unpublished data). The stromal cell line MS-5,
on the other hand, produced little VEGF, and VEGF release
did not change with IR (Fig. 4 D). Using a more complex
BM-derived stromal cell population from MMP-9 /  ani-
mals, VEGF secretion did not change before (1961   143
pg/mL) or after IR (2107   150 pg/mL).
Which cell type produces KitL? We show that IR in-
creased KitL release by MS-5 cells in vitro, which could be
Figure 4. MMP-9–dependent release of VEGF by mast cells and 
of KitL by stromal cells promotes mast cell migration, a necessary 
requirement for ischemic regeneration. (A, B) HL ischemia was 
induced in MMP-9 /  and MMP-9 /  mice, and mice were irradiated 
with 2 Gy or left unirradiated. Sections of ischemic muscle (A) and skin 
(B) were stained with Toluidine blue to detect mast cells (a–m). Arrows 
indicate Toluidine positive mast cells in the ischemic muscle tissue. 
Adjacent sections of muscle tissue were used for VEGF in situ hybridization 
(e–h) and immunostaining for VEGFR-2 (i–l). (A, i and l) Arrows indicate 
the same mast cells stained on adjacent sections for VEGFR2 in ischemic 
muscle tissue. (A, k) Arrow indicates a VEGFR2 positively stained vessel 
in ischemic muscle tissue. (B) Arrows indicate Toluidine positively 
stained mast cells in the muscle tissue. *P   0.05 (three independent 
experiments, 3 mice/group; original magnification  100). (C) BM-derived 
mast cells from MMP-9 /  and MMP-9 /  mice were plated into transwells. 
The chemoattractants KitL and VEGF were added to the lower chamber. 
Data are shown as a percentage of migrated cells (two independent 
experiments; *P   0.05 for migration of MMP-9 /  vs. MMP-9 /  
cells). (D) Mast cells from MMP-9 WT mice, a mast cell line PT18, and 
stromal cells (MS-5) were cultured in serum-free medium overnight. 
Supernatants were assayed for VEGF via ELISA. *P   0.05 comparing 
Media with 2 Gy or 2 Gy   KitL groups or 2 Gy group with 2 Gy   KitL 
group. (E) BM stromal cells and BM-derived mast cells from MMP-9 /  
mice were irradiated with 2 Gy in the presence and absence of MPI CGS 
27023A. After 24 h in culture, supernatants were assayed for KitL (two 
independent experiments). *P   0.05 comparing Media versus MPI or 
2 Gy and 2 Gy versus 2 Gy   MPI. (F–G) HL ischemia was induced in 
Sl/Sld and WBB6F1 /  mice. Groups of mice were irradiated with 2 Gy 
or were left unirradiated (n   7). (F) Mice were analyzed via laser Doppler 
for blood perfusion in the ligated limb (left and right column) or were 
evaluated macroscopically (middle column). (G) Quantification of blood 
flow (Flux) after vessel ligation. Insert: percentage of limb rescue. *P   0.05 
comparing WT versus Sl/Sld mice and HL versus HL   2 Gy group. Error 
bars indicate mean   SEM.JEM VOL. 202, September 19, 2005 745
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blocked by a synthetic metalloproteinase inhibitor (Fig. 4 E).
In contrast, mast cells only showed baseline secretion of KitL
and no change in KitL production after IR. Thus our results
indicate cooperation between two cell types in mobilizing
mast cells: stromal cells produce KitL, while mast cells pro-
duce VEGF in response to IR, and both depend on MMP-9.
To test if IR-induced vasculogenesis/angiogenesis is de-
pendent on mast cells in vivo, mast cell–deficient Sl/Sld mice
and WBB6F1 /  controls received 2 Gy IR after induction
of HL ischemia. Necrosis was macroscopically detectable on
day 7 in Sl/Sld, but not as profound in the WT mice (Fig. 4
F). By day 14, blood flow recovered in WBB6F1 /  litter-
mates, whereas Sl/Sld mice showed complete limb amputa-
tion (Fig. 4, F and G). IR accelerated the ischemic recovery
in WBB6F1 /  mice, but not in Sl/Sld mice (Fig. 4 G).
When Sl/Sld mice with HL ischemia were treated with IR,
all mice died by day 14. These data support the hypothesis
that improved angiogenesis after IR is driven by mast cells.
rKitL protects against lethal IR and increases the number
of progenitors (21). Mobilization of hematopoietic (Fig. 5 A)
and endothelial progenitors (Fig. 5 B) following HL is-
chemia was similar in WBB6F1 /  and Sl/Sld mice; how-
Figure 5. Irradiation-induced angiogenesis is dictated by MMP-9–
mediated factor release from mast and stroma cells and incorporation 
of BM-derived cells. (A–C) HL ischemia was induced in Sl/Sld and 
WBB6F1 /  mice, followed by 2 Gy IR or no IR (n   7). PBMCs were analyzed 
for the presence of CFU-Cs (A) and CFU-ECs (B). (C) Plasma VEGF was 
determined (n   7/group). (D) HL ischemia was induced in MMP-9 /  
mice followed by 2 Gy IR. Mice were subdivided into groups receiving 
neutralizing mAbs against VEGFR-1, VEGFR-2 or a combination of both 
mAbs. (a) Blood flow was determined. Insert: Percentage of mice showing 
limb rescue after ligation. (b) Macroscopic pictures taken of ischemic and 
contralateral limb 7 d after ligation (*P   0.05 comparing WT /    HL   
2 Gy against VEGFR treatment groups). (E) Administration of rVEGF intra-
peritoneally augmented MMP-9 staining (arrows indicate MMP-9 staining, 
brown) in the BM (a) and increased levels for KitL in the plasma of 
VEGF-treated mice (b) (*P   0.05 comparing VEGF with PBS control). 
(E, F) MMP-9 /  mice received vessel ligation (red bar) followed by local 
IR (white arrow) with 2 Gy of the ischemic or the contralateral, nonischemic 
limb. Arrows indicate that the specified limb received local irradiation, 
whereas the contralateral limb did not. Macroscopic tissue recovery (on 
day 16) and blood flow as determined via Doppler analysis on day 10 are 
shown. (G) From day 1–14, PBMCs from irradiated and unirradiated donor 
mice were isolated and injected daily into C57BL/6 recipients after HL ischemia 
surgery. Blood flow was determined on day 7. (H) Bilateral vessel ligation 
(both limbs) was performed in C57BL/6 mice. Groups of mice received 2 Gy 
IR unilateral (left, lt). The nonirradiated limb (right, rt) served as a control. 
Blood flow was quantified via laser Doppler analysis (*P   0.05 comparing 
bilateral HL vs. bilateral HL   local 2 Gy). (I) C57BL/6 mice were transplanted 
with GFP  BMNCs. After cell engraftment, mice underwent vessel ligation 
with or without 2 Gy IR. (left). Ischemic muscle tissue was stained with 
SMA-Cy Red. (right). The percentage of GFP  vessels per total vessels is 
shown. (A–C) *P   0.05 comparing WT /    HL against WT /    HL   
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ever, IR-induced progenitor mobilization was completely
blocked in Sl/Sld but not WBB6F1 /  mice, indicating that
IR-induced progenitor mobilization depends on the pres-
ence of KitL. In confirmation of our data that mast cells are
the source of VEGF following HL ischemia and IR, we de-
tected lower VEGF plasma levels in Sl/Sld mice after HL is-
chemia as compared with WBB6F1 /  controls (Fig. 5 C);
in addition, IR enhanced VEGF plasma levels in WBB6F1 / 
but not Sl/Sld mice.
If VEGF signaling following IR promotes angiogenesis
under ischemic conditions, administration of neutralizing
antibodies against VEGFR-1 and VEGFR-2 should prevent
IR-induced angiogenesis. MMP-9 /  mice received vessel
ligation followed by TBI of 2 Gy (Fig. 5 D). Macroscopic
examination at day 7 revealed that 2 Gy of IR completely
prevented signs of limb necrosis, whereas amputation oc-
curred following HL ischemia (Fig. 5 D, b). The effect of IR
in preventing tissue necrosis/amputation was blocked
by anti–VEGFR-2 treatment or a combination of anti–
VEGFR-1 and anti–VEGFR-2 treatment by day 10, but was
only partially inhibited in mice receiving anti–VEGFR-1 by
day 14 (Fig. 5 D). Single injections of anti–VEGFR-1 re-
sulted in necrosis but not complete limb amputation.
Administration of rVEGF intraperitoneally caused up-
regulation of MMP-9 in BM (Fig. 5 E, a) and increased
plasma levels of KitL in treated mice (Fig. 5 E, b). If VEGF
promotes mast cell migration into ischemic tissue, blockade
of VEGF signaling using VEGFR-1 or VEGFR-2 mAbs
should decrease the number of mast cells in the muscle tissue
following HL ischemia and/or IR. Indeed, HL ischemia–
induced mice treated with VEGFR-2 mAbs or a combina-
tion of VEGFR-1 and VEGFR-2 mAbs showed a decreased
number of mast cells in the muscle tissue compared with un-
treated controls (Fig. S2 J). Administration of VEGFR-1 di-
minished the number of mast cells partially. These data un-
derscore the importance of VEGF signaling in regulating the
number of resident mast cells under “stress conditions.”
IR promotes angiogenesis by altering 
the tissue microenvironment
Local low-dose IR rather than TBI would be a more rele-
vant treatment for future clinical applications by reducing
systemic side effects. Therefore, C57BL/6 mice received
unilateral HL ischemia. Groups of mice were then adminis-
tered local IR (2 Gy) of the ischemic limb, IR of the con-
tralateral nonischemic limb, or no IR. IR of the contralat-
eral, nonischemic limb controlled for effects due to BM IR.
Muscle tissue regeneration was faster in mice when the is-
chemic limb was irradiated compared with nonirradiated
controls (Fig. 5 F). Local IR of the contralateral, nonis-
chemic limb did not result in faster tissue regeneration.
Thus, activation of the BM alone was not sufficient to pro-
mote angiogenesis. These data implicate that IR of the is-
chemic tissue, but not of nonischemic tissue, “conditions”
the ischemic tissue microenvironment and is critical for IR-
induced angiogenesis.
To understand if progenitors mobilized after IR alone
could improve vasculogenesis/angiogenesis, PBMCs iso-
lated from irradiated and unirradiated donor mice were
transplanted into groups of C57BL/6 recipient mice after
HL ischemia surgery. We observed HL ischemic recovery
in mice transplanted with PBMCs from unirradiated mice,
but not in mice transplanted with PBMCs isolated from 2
Gy irradiated donors (Fig. 5 G). These data implicated
that circulating cells induced by IR alone were not suffi-
cient to duplicate the previously observed angiogenesis-
promoting effects of IR.
Do BM-derived cells play any role at all in IR-induced
angiogenesis under ischemic conditions? When C57BL/6
mice reconstituted with donor GFP-expressing BM cells re-
ceived HL surgery and 2 Gy IR, BM-derived GFP  cells con-
tributed to vessel formation in muscle tissue of mice that had
undergone HL ischemic surgery (Fig. 5 I). These BM-derived
cells were covered by smooth muscle actin (SMA)  cells, indi-
cating their incorporation into mature vessels. The highest
Figure 6. Irradiation modulates neo-angiogenesis within the ischemic 
microenvironment through VEGF release from mast cells. IR induces 
up-regulation of MMP-9, resulting in the release of KitL. KitL not only 
promotes mobilization of progenitors into circulation, which ultimately 
can be incorporated in ischemic tissue, but also acts as a potent proliferation 
and migration factor for mast cells. In a partly MMP-9–dependent manner, 
IR enhances VEGF release from mast cells, which further promote local 
accumulation of mast cells. VEGF directly can locally support angiogenesis 
and can further up-regulate MMP-9.JEM VOL. 202, September 19, 2005 747
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density of donor-derived GFP  vessels was found in animals
that had received HL ischemic surgery and 2 Gy IR (82%)
(Fig. 5 I). Donor-derived GFP  cells were undetectable in
unirradiated mice without HL ischemia (0%). These data im-
ply that IR applied under ischemic conditions promotes in-
corporation of BM-derived cells into regenerating vasculature.
To understand whether IR conditions the local ischemic
microenvironment to promote mast cell incorporation, we
induced bilateral HL ischemia in WBB6F1 /  mice. IR of
one leg resulted in faster recovery of blood flow compared
with the unirradiated ischemic limb (Fig. 5 H). Increased
numbers of mast cells were found in muscle tissue of the ir-
radiated but not the nonirradiated limb (Fig. S2 K, a and b).
Plasma levels for VEGF and KitL after bilateral HL ischemia
further increased following loco-regional IR (Fig. S2, K, c).
DISCUSSION
We report that low-dose IR promotes neovascularization in
the ischemic limb. We provide in vitro and in vivo evidence
that mast cells act as a key cellular mediator orchestrating the
IR-induced formation of a new vascular network (Fig. 6). IR
mediates neovascularization by promoting the release of
VEGF from mast cells in a partly MMP-9–dependent man-
ner. VEGF can further up-regulate MMP-9 in the ischemic
microenvironment, causing improved mast cell migration.
On the other hand, IR-induced KitL increases the number of
mast cells in the ischemic tissue and might promote recruit-
ment, incorporation, and differentiation of progenitors into
regenerating tissue. The critical importance for mast cells and
VEGF in IR-mediated neovascularization under ischemic
conditions was underscored by blocking studies using mast
cell–deficient Sl/Sld mice and blocking Abs against VEGFR-1
and VEGFR-2 to inactivate VEGF signaling.
These data introduce a new mechanism, how IR under
ischemic conditions alters the cellular and chemical compo-
sition of the ischemic microenvironment. IR promotes tis-
sue regeneration by inducing the expression of genes in mast
and stroma cells to further promote incorporation of BM-
derived cells, mast cells, pericytes/SMCs, and possibly pro-
genitors to the ischemic side, providing vascular stability and
further release of angiogenic factors through the control of
proteases. IR has been shown to up-regulate MMP-9 in ECs
(22) and to increase the production of nitric oxide (NO) and
endothelial nitric oxide synthase (eNOS) (6). NO activates
MMP-9 via nitrosylation (23) and improves endothelial and
mural cell migration (24). Both NO and eNOS play a criti-
cal role in VEGF-induced angiogenesis (25). Mice lacking
eNOS show an MMP-9–dependent defect in progenitor cell
mobilization and angiogenesis (26). We speculate that the
observed IR-induced up-regulation of MMP-9 might in-
volve the NO pathway, but further studies are needed.
Impaired tissue revascularization in MMP-9–deficient mice
BM-derived cells might directly contribute to newly forming
vessels or act as bystander cells of the stromal compartment,
where they produce cytokines/chemokines (15, 27, 28). He-
matopoietic progenitors are mobilized after low-dose IR
(29). We show that IR-induced progenitor mobilization is
dependent on KitL/mast cells, because no progenitor mobili-
zation was observed in Sl/Sld mice. BM-derived GFP  cells
contributed to vessel formation in ischemic tissues, and IR
improved BM cell incorporation in irradiated ischemic tis-
sues. We demonstrated that low-dose IR through VEGF re-
leased from mast cells up-regulates MMP-9 in BM stroma
and ECs. These data are in accordance with the idea that IR
conditions the ischemic microenvironment (mast or stromal
cells) to release soluble factors (VEGF or KitL), which can at-
tract circulating cells and promote their tissue incorporation.
Another hint that IR activates the ischemic microenvi-
ronment came from the finding that elevated levels of plasma
SDF-1, a chemokine produced by stroma cells, was detect-
able (30). Progenitor mobilization following HL ischemia
has been attributed to increased plasma SDF-1 levels (31).
Further blocking studies are needed to determine where
SDF-1 fits into our pathway of IR-induced angiogenesis.
This report is the first to demonstrate that IR can mobi-
lize CEPs, and that this mobilization is dependent on MMP-9
and KitL, because it did not take place in MMP-9 /  and
Sl/Sld mice. We showed reduced angiogenic revasculariza-
tion in MMP-9 /  mice on a CD1 background, confirming
data by others using MMP-9 /  mice in C57BL/6 and
129Sv backgrounds (32, 33). Faster ischemic recovery in
MMP-9 /  irradiated mice was associated with improved
vessel formation. In contrast, newly formed microvessels in
MMP-9 /  mice showed decreased pericyte coverage and
slower ischemic recovery after IR. These data are in accor-
dance with studies showing that VEGF pretreatment of
VEGFR-1  SMCs activates MMP-9 (34) and that MMP-
9 /  SMCs have decreased cell migration compared with
MMP-9 /  cells in vitro (35).
Mast cell migration and VEGF release from mast cells 
are defective in MMP-9 /  mice
The radiosensitivity of white spotting and Sl/Sld mice has been
attributed to a role for KitL in the proliferation of BM-derived
mast cells (36). If IR results in the release of KitL, more c-kit 
mast cells should be found in irradiated tissue. Indeed, in the re-
covery phase after IR, concomitant with increased KitL plasma
levels, the number of mast cells was higher in muscle tissue of
MMP-9 /  mice compared with MMP-9 /  mice.
Mast cells migrate into tissues via blood circulation as im-
mature cells and undergo complete maturation in the tissues
(37). Murine mast cells migrate toward VEGF (20) and ex-
press VEGFR-2 (38). We showed that circulating mast cell–
like cells express c-kit and VEGFR-2 and that VEGF-
induced mast cell migration was partially blocked using
VEGFR mAbs. We demonstrated that MMP-9 /  mast cells
failed to migrate toward KitL and VEGF. These data indicate
that VEGF improves mast cell migration by further activating
MMPs, because a synthetic MPI blocked this migration. In-
terestingly, a study by Tanaka et al. showed that MMP-9 pro-
moted the migration of mast cell precursors into tissues (5).LOW-DOSE IRRADIATION PROMOTES TISSUE REVASCULARIZATION | Heissig et al. 748
Mast cells contain extracellular matrix–degrading MMPs
and constitutively secrete VEGF (39, 40). We demonstrate
that VEGF production partly depends on the presence of
MMP-9, because baseline VEGF release was low in MMP-
9 /  mast cells in vitro. Irradiated MMP-9 /  mast cells se-
creted more VEGF than unirradiated mast cells, consistent
with a study showing that VEGF gene expression was up-
regulated in irradiated versus unirradiated cells (7). Blocking
VEGF signaling using neutralizing mAbs against VEGFR-1
and VEGFR-2 prevented mast cell migration and IR-
induced vasculogenesis/angiogenesis. Interestingly, we de-
tected increased levels of histamine in the plasma of IR ani-
mals as early as 6 h, indicating that mast cell activation had
taken place.
Our data show that mast cells are critical in ischemic re-
covery and IR-induced angiogenesis: ischemic regeneration
was delayed, the number of IR-induced circulating progeni-
tors reduced, and the VEGF plasma levels following IR were
significantly lower in mast cell–deficient Sl/Sld mice than in
unirradiated WT mice. Even though the release of VEGF
and KitL depends in part on MMP-9, MMP-9 /  mice do
not completely lack these factors and show growth factor el-
evation to some degree after ischemia and IR. The leakiness
in the system might explain why improved tissue vascular-
ization was detectable in MMP-9 /  mice, albeit at lower
levels. It is also conceivable that MMP-9–independent an-
giogenesis-modulating factors are released from mast cells
under ischemic conditions, but future studies will be neces-
sary. These data support our current model that VEGF and
mast cells, partly under the control of MMP-9, are critical in
the angiogenesis-promoting effect of IR. It is conceivable
that growth factor–independent IR can modulate the vascu-
lar tonus of the distal vasculature (41).
Clinical implications
The results of the present study have important implications
for the use of radiotherapy in nonmalignant and malignant
diseases. We demonstrated the clinical potential of low-dose
IR to induce neovascularization in ischemia-associated dis-
eases. However, potential adverse effects due to the release
of KitL and/or activation of mast cells might occur, includ-
ing mast cell degranulation with increased pruritus, increased
melanization of the epidermis, and allergic-like reactions
such as urticaria, with or without respiratory symptoms (42).
Likewise, long-term studies are needed to rule out negative
side effects resulting from local IR. We propose that IR
modulates the ischemic and possibly tumor microenviron-
ment via MMP-9–mediated cytokine and angiogenic factor-
driven mast cell and progenitor recruitment. We identified
mast cells as a major source of VEGF release, which is
known to promote tumor-angiogenesis. Tumor growth is
controlled by angiogenesis. In cancer patients, the cytotoxic
effect of low-dose IR on tumor cells might outweigh the
IR-induced proangiogenic effects, resulting in a net tumor
mass reduction. On the other hand, our model might shed
light into clinical settings in which a tumor returned despite
initial killing of tumor cells. Radio-resistant mast cells,
whose number could be further increased by IR-induced re-
lease of KitL might guide those processes (21).
MATERIALS AND METHODS
Animals
MMP-9 /  and MMP-9 /  mice were used after  10 back crosses to CD1
mice (14). KitL WT (WBB6F1 / ) and KitL-deficient (Sl/Sld) and C57BL/6
mice were purchased from SLC. Mice expressing GFP under a  -actin pro-
moter were provided by A. Urabe (Juntendo University, Tokyo, Japan).
Animal studies had been approved by the Animal Review Board of Jun-
tendo University, Tokyo.
Irradiation in vivo
MMP-9 /  and MMP-9 /  mice were irradiated with 1, 2, 6.5, or 9.5 Gy
(Caesium Gy source). Sl/Sld and WBB6F1 /  littermates were irradiated
with 2 Gy. For local IR (2 Gy), mice were kept in a radio-dense 2-cm-
thick lead cage; only the irradiated limb left the cage.
VEGF administration
MMP-9 /  mice received rVEGF 300 ng/mouse/d intraperitoneally.
PBMC transplantation
PBMCs (2   106/mouse) from irradiated (2 Gy) and unirradiated C57BL/6
mice (from day 0–16) were injected intravenously into unirradiated HL is-
chemia–induced mice.
HL model
Unilateral or bilateral ligation of the femoral artery and vein and cutaneous
vessels branching from the caudal femoral artery side branch were performed.
Groups of MMP-9 /  and MMP-9 /  mice or Sl/Sld and WBB6F1 /  lit-
termates were then irradiated with or without 2.0 Gy. Tissue sections from
the lower muscles of ischemic limbs were harvested. Thermography of the
collateral region was performed using a Lisca PIM II camera (Gambro). A la-
ser Doppler perfusion image analyzer (Moor Instruments) recorded blood
flow postoperatively. Blood was collected via retro-orbital bleeding using he-
parinized capillaries. Plasma samples were stored at  80 C. White blood cell
counts were determined. PBMCs were isolated from heparinized blood after
centrifugation over Lympholyte-M (Cedarlane).
In vivo blocking experiments
Unilateral HL ischemia–inducing surgery was performed on MMP-9 / ,
WBB6F1 / , or Sl/Sld mice receiving 2 Gy or no IR. Mice were coin-
jected intraperitoneally with 800  g anti–mouse VEGFR-1 (MF-1), anti–
mouse VEGFR-2 (DC101), or IgG at 2-day intervals starting at day 0 (4).
Histological assessment
Paraffin-embedded sections were deparaffinized and stained with hematox-
ylin-eosin. Vascular structures within the BM with EC morphology, which
contained erythrocytes, were counted as capillaries in hematoxylin-eosin–
stained BM. The mean number of capillaries per square millimeter (capillary
density) of vWF stained slides was counted. The mean ischemic area per
square millimeter (n   10) of hematoxylin-eosin–stained slides was deter-
mined using an image analyzer (Carl Zeiss Vision, Hallbergmoss). Necrotic
muscle fibers were identified via morphology, differential eosin staining,
and presence of infiltrating cells near degenerating fibers. Paraffin sections of
muscle or skin sections were stained with Toluidine blue O, and mast cells
were counted under a light microscope.
Deparaffinized BM sections were stained for MMP-9 (7-11C) or a mu-
rine Ab against MMP-9 as described (14). Muscle sections were stained with
CD31 (BD Biosciences, MEC13.3), vWF (DakoCytomation) or VEGFR-2
(DC101). vWF stained sections were developed with 3 ,3 -diaminobenzi-
dine. ECs were identified using rat mAb against mouse CD31 followed by
biotin-conjugated Goat anti–rat IgG and Cy3-conjugated streptavidin (Alexa
594, Molecular Probes) staining. SMCs were identified using mouse anti-JEM VOL. 202, September 19, 2005 749
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human SMA (1A4) followed by biotin-conjugated Goat anti–mouse IgG
and FITC-conjugated streptavidin (Alexa 488, Molecular Probes).
In situ hybridization for VEGF
VEGF was detected in muscle sections using a murine-specific probe for
VEGF as described previously (43).
In vitro assays
Murine BM cultures. Murine BM cells (106 cells) from MMP-9 /  and
MMP-9 /  isolated before and after TBI were placed in serum-free me-
dium (X-VIVO-15) overnight. Supernatants were analyzed via Western
blotting using murine mAb to MMP-9 as described previously (14).
Murine PBMC isolation. Groups of MMP-9 /  and MMP-9 /  mice
were set up in which HL ischemia was followed by 2 Gy IR or no IR.
Mice were bled on day 7. PBMCs were labeled with VEGFR-2/Cy2 and
c-kit/PE, separated using MoFlo. Cytospins were prepared from the cell
fractions, which were stained with Toluidine blue.
PT18 and MS-5 cultures. PT18 cells (5   105 cells/mL) and a confluent
layer of MS-5 cells were cultured for 48 h in serum-free medium. Cells
were irradiated using a dose of 2 Gy or were not irradiated. Supernatants
were stored at  20 C.
Murine BM mast cell cultures. BM-derived mast cells were produced
by culturing MMP-9 /  and MMP-9 /  BM cells in RPMI 1640 supple-
mented with 0.075% sodium bicarbonate (Sigma), 1 mM nonessential
amino acids (GIBCO BRL), 5.5   10 5 M 2-ME (Wako), 1 mM sodium
pyruvate (ICN Biomedicals), 10% FBS (GIBCO BRL), and 10% WEHI-3–
derived conditioned medium. Mast cells from 3-wk cultures were cultured
over night in serum-free medium (Ex Vivo 15). Supernatants were stored at
 20 C. 3-wk-old BM mast cell cultures contained  97% c-kit  cells by
FACS and 95% Toluidine blue  cells.
Mast cell transmigration. Mast cells derived from MMP-9 /  and
MMP-9 /  BM cultures were added to 5- m pore size transwell inserts
(Costar). Murine rKitL (100 ng/mL; PeproTech) or rVEGF (200 ng/mL;
PeproTech) were added to the lower chamber with/without neutralizing
mAbs against murine VEGFR1 (MF-1), VEGFR1 (DC101), the MPI CGS
27023A (1 nM; Novartis), and neutralizing mAbs against KitL (R&D Sys-
tems) that were added to both chambers. Transmigrated cells were ex-
pressed as the percentage of transmigrated cells.
Hematopoietic progenitor assay. PBMCs (105 cells/plate) or BM
mononuclear cells (BMNCs) (105 cells/plate) were assayed as described pre-
viously (14).
Endothelial progenitor assay. PBMCs or BMNCs before and obtained
at various time points after IR (2 Gy) were cultured as described previously
(14). To determine the EC origin, adherent cells were stained with anti–
mouse VEGFR-2 (Avas-12a1, PharMingen), followed by peroxidase-con-
jugated streptavidin incubation (DakoCytomation), and visualized using an
AEC  Substrate-Chromosome System (DakoCytomation). Cultures were
costained using rat monoclonal anti–mouse CD45 (BD Biosciences) to ex-
clude leukocytes, followed by alkaline phosphatase–labeled streptavidin
(Vector), and visualized using Nitro blue Tetrazolium Chloride (DakoCy-
tomation). VEGFR-1  and VEGFR-2  cells were quantified via FACS us-
ing Cy2-labeled mAb to VEGFR-1 (MF-1) and VEGFR-2 (DC101).
Zymography. Supernatants from BM cells from MMP-9 WT mice be-
fore and after IR with 6.5 Gy and 2 Gy were cultured overnight in serum-
free medium. Supernatants were analyzed as described previously (14).
Immunoassay. In plasma/culture supernatants SDF-1, VEGF, PlGF,
KitL, MCP-1, and pro–MMP-9 were measured via ELISA (R&D Systems).
TGF-  plasma levels were assayed using a TGF-  ELISA kit (Genzyme
Boston). Plasma obtained 20 min after IR was analyzed for histamine via
ELISA (ImmunoTECH).
Statistical analysis
Data were analyzed using an unpaired two-tailed Student’s t test and are ex-
pressed as the mean   SEM. P values less than 0.05 were considered significant.
Online supplemental material
Fig. S1 shows MMP-9 but not MMP-2 expression and plasma levels for
SDF-1 and PlGF and BM recovery of VEGFR-1  and VEGFR-2  cells
following IR with 6.5 Gy. Fig. S2 shows progenitor mobilization after 2 Gy
IR and includes data on KitL, PlGF, MCP-1, TGF- , and histamine release
following HL ischemia in combination with 2 Gy IR. Fig. S2 also contains
data on VEGF release from mast cells in vitro and data on the number of
mast cells in muscle tissues after mice had been treated with neutralizing an-
tibody against VEGFR-1 and VEGFR-2, as well as data on the number of
mast cells and the release of VEGF and KitL in mice following bilateral liga-
tion of the femoral artery and vein. Online supplemental material is avail-
able at http://www.jem.org/cgi/content/full/jem.20050959/DC1.
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